BDX · 10-Q · 2026Q2 · Full report
Segment Revenue Performance
BECTON DICKINSON & CO · 2026-08-06 · Importance 49 · Surprise 32 · No source text
Third-quarter revenue increased 4.5% in Medical Essentials to $1.675 billion, 4.9% in Connected Care to $1.224 billion, and 6.4% in Interventional to $1.414 billion. BioPharma Systems revenue increased 6.6%, driven by double-digit prefillable-solution growth in biologic drugs and GLP-1 delivery products, partly offset by lower vaccine demand. Connected Care Advanced Patient Monitoring grew 10.9%, led by Acumen IQ Cuff, Acumen IQ Sensor and consumables, while Medical Essentials Specimen Management grew 8.7% on stronger BD Vacutainer sales. Nine-month revenue increased 3.3% in Medical Essentials to $4.918 billion, 5.1% in Connected Care to $3.475 billion, 4.1% in BioPharma Systems to $1.689 billion and 6.5% in Interventional to $4.101 billion.
Key facts
- Medical Essentials total revenues for the three months ended June 30, 2026 were $1,675 million, up 4.5% (FXN change 3.2%, estimated FX impact 1.3%). source
- Medication Delivery Solutions revenues in Medical Essentials for the three months ended June 30, 2026 were $1,164 million, up 2.8% (estimated FX impact 1.2%, FXN change 1.6%). source
- Medical Essentials nine months ended June 30, 2026 total revenues were $4,918 million, up 3.3% (estimated FX impact 1.8%, FXN change 1.5%). source
- Connected Care total revenues for the three months ended June 30, 2026 were $1,224 million, up 4.9% (estimated FX impact 0.5%, FXN change 4.4%). source
- Connected Care nine months ended June 30, 2026 total revenues were $3,475 million, up 5.1% (estimated FX impact 0.9%, FXN change 4.2%). source
- BioPharma Systems nine months ended June 30, 2026 total revenues were $1,689 million, up 4.1% (estimated FX impact 2.5%, FXN change 1.6%). source
- Interventional total revenues for the three months ended June 30, 2026 were $1,414 million, up 6.4% (estimated FX impact 0.9%, FXN change 5.5%). source
- Interventional nine months ended June 30, 2026 total revenues were $4,101 million, up 6.5% (estimated FX impact 1.2%, FXN change 5.3%). source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +5.0% | Interventional nine months ended June 30, 2026 total revenues were $4,101 million, up 6.5% (estimated FX impact 1.2%, FXN change 5.3%). |
| revenue | positive | realized | +3.4% | Connected Care nine months ended June 30, 2026 total revenues were $3,475 million, up 5.1% (estimated FX impact 0.9%, FXN change 4.2%). |
| revenue | positive | realized | +3.1% | Medical Essentials nine months ended June 30, 2026 total revenues were $4,918 million, up 3.3% (estimated FX impact 1.8%, FXN change 1.5%). |
| revenue | positive | realized | +1.7% | Interventional total revenues for the three months ended June 30, 2026 were $1,414 million, up 6.4% (estimated FX impact 0.9%, FXN change… |
| revenue | positive | realized | +1.5% | Medical Essentials total revenues for the three months ended June 30, 2026 were $1,675 million, up 4.5% (FXN change 3.2%, estimated FX… |
| revenue | positive | realized | +1.3% | BioPharma Systems nine months ended June 30, 2026 total revenues were $1,689 million, up 4.1% (estimated FX impact 2.5%, FXN change 1.6%). |
| revenue | positive | realized | +1.2% | Connected Care total revenues for the three months ended June 30, 2026 were $1,224 million, up 4.9% (estimated FX impact 0.5%, FXN change… |
| revenue | positive | realized | +0.6% | Medication Delivery Solutions revenues in Medical Essentials for the three months ended June 30, 2026 were $1,164 million, up 2.8%… |